Nicotine patch vs. nicotine lozenge for smoking cessation: An effectiveness trial coordinated by the Community Clinical Oncology Program

Drug and Alcohol Dependence

Volumn 107, Issue 2-3, 2010, Pages 237-243

  Schnoll, Robert A ^a   Martinez, Elisa ^a   Tatum, Kristina L ^b   Glass, Marcella ^b   Bernath, Albert ^c   Ferris, Daron ^d   Reynolds, Patrick ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Moderators; Nicotine dependence; Nicotine replacement therapy; Smoking cessation

Indexed keywords

CARBON MONOXIDE; NICOTINE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG PREFERENCE; EMOTIONAL STRESS; FEMALE; HUMAN; HYPERSALIVATION; LOZENGE; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; MULTICENTER STUDY; NICOTINE REPLACEMENT THERAPY; OPEN STUDY; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SMOKING CESSATION; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; BREATH TESTS; CARBON MONOXIDE; COGNITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; PHILADELPHIA; SMOKING CESSATION; STRESS, PSYCHOLOGICAL; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 77649187595     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.11.001     Document Type: Article

References (30)

1. Alterman A.I., Gariti P., Cook T.G., Cnaan A. Nicodermal patch adherence and its correlates. Drug Alcohol. Depend. 1999, 53:159-165.
2. Bader P., McDonald P., Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tob. Control 2009, 18:34-42.
3. Benowitz N.L., Jacob P., Ahijevych K., Jarvis M.J., Hall S., LeHouezec J. Biochemical verification of tobacco use and cessation. Nicotine Tob. Res. 2002, 4:149-159.
4. Brown R.A., Burgess E.S., Sales S.D., Whiteley J.A., Evans D.M., Miller I.W. Reliability and validity of a smoking timeline follow-back interview. Psychol. Addict. Behav. 1998, 12:101-112.
5. Evans D.E., Drobes D.J. Nicotine self-medication of cognitive-attentional processing. Addict. Biol. 2009, 14:32-42.
6. Fagerström K.O., Tejding R., Westin A., Lunell E. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?. Tob. Control 1997, 6:311-316.
7. Fiore M.C., Jaén C.R., Baker T.B., Bailey W.C., Benowitz N.L., Curry S.J., Dorfman S.F., Froelicher E.S., Goldstein M.G., Healton C.G., Henderson P.N., Heyman R.B., Koh H.K., Kottke T.E., Lando H.A., Mecklenburg R.E., Mermelstein R.J., Dolan Mullen P., Orleans C.T., Robinson L., Stitzer M.L., Tommasello A.C., Villejo L., Wewers M.E. Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline 2008, U.S. Department of Health and Human Services, Public Health Service, Rockville, MD.
8. Gehricke J.G., Loughlin S.E., Whalen C.K., Potkin S.G., Fallon J.H., Jamner L.D., Belluzzi J.D., Leslie F.M. Smoking to self-medicate attentional and emotional dysfunctions. Nicotine Tob. Res. 2007, 9:S523-S536.
9. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
10. Hasford J., Fagerstrom K.O., Haustein K.O. A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation. Eur. J. Clin. Pharmacol. 2003, 59:443-447.
11. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom test for nicotine dependence: A revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991, 86:1119-1127.
12. Horn D., Waingrow S. Some dimensions of a model for smoking behavior change. Am. J. Public Health 1966, 56:21-56.
13. Hughes J.R., Keely J.P., Niaura R.S., Ossip-Klein D.J., Richmond R.L., Swan G.E. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob. Res. 2003, 5:13-25.
14. Hughes J.R., Shiffman S., Callas P., Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob. Control 2003, 12:12-27.
15. Jonk Y.C., Sherman S.E., Fu S.S., Hamlett-Berry K.W., Geraci M.C., Joseph A.M. National trends in the provision of smoking cessation aids within the Veterans Health Administration. Am. J. Manage. Care 2005, 11:77-85.
16. Jorenby D.E., Hays J.T., Rigotti N.A., Rigotti N.A., Azoulay S., Watsky E.J. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
17. Leischow S.J., Valente S.N., Hill A.L., Otte P.S., Aickin M., Holden T., Kligman E., Cook G. Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. Exp. Clin. Psychopharmacol. 1997, 5:54-64.
18. Lerman C., Audrain J., Orleans C.T., Boyd R., Gold K., Main D., Caporaso N. Investigation of mechanisms linking depressed mood to nicotine dependence. Addict. Behav. 1996, 21:9-19.
19. Lerman C., Caporaso N., Main D., Audrain J., Boyd N.R., Bowman E.D., Shields P.G. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol. 1998, 17:56-62.
20. Lerman C., Kaufmann V., Rukstalis M., Patterson F., Perkins K., Audrain-McGovern J. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann. Intern. Med. 2004, 140:426-433.
21. Pierce J.P., Gilpin E.A. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002, 288:1260-1264.
22. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weille E., Herqueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59:22-33.
23. Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. Addiction 2007, 102:809-814.
24. Shiffman S., Dresler C.M., Hajek P., Gilburt S.J., Targett D.A., Strahs K.R. Efficacy of a nicotine lozenge for smoking cessation. Arch. Intern. Med. 2002, 162:1267-1276.
25. Shiffman S., Rolf C.N., Hellebusch S.J., Gorsline J., Gorodetzky C.W., Chiang Y.K., Schleusener D.S., Di Marino M.E. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction 2002, 97:505-516.
26. Shiffman S., Shadel W.G., Niaura R., Khayrallah M.A., Jorenby D.E., Ryan C.F., Ferguson C.L. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacol. (Berl.) 2003, 166:343-350.
27. Stead L., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2008, 21:CD000146.
28. Velicer W.F., Diclemente C.C., Rossi J.S., Prochaska J.O. Relapse situations and self-efficacy: an integrative model. Addict. Behav. 1990, 15:271-283.
29. Waters A.J., Shiffman S., Sayette M.A., Paty J.A., Gwaltney C.J., Balabanis M.H. Cue-provoked craving and nicotine replacement therapy in smoking cessation. J. Consult. Clin. Psychol. 2004, 72:1136-1143.
30. West R., Hajek P., Nilsson F., Foulds J., May S., Meadows A. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacol. (Berl.) 2001, 153:225-230.